Alps Group

Alps Group ROA

The Return on Assets (ROA) of Alps Group (ALPS) as of Oct 17, 2026 is -26.45 %. In the previous year, Return on Assets (ROA) was 4.57 % — a change of -678.33% (lower).

ROA

-26.45 %

YoY

-678.33%

Last updated:

In 2024, Alps Group's return on assets (ROA) was -26.45 %, a -678.33% increase from the 4.57 % ROA in the previous year.

The Alps Group ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2022
0.19 USD
Jan 1, 2023
4.57 USD
Jan 1, 2024
-26.45 USD
The Alps Group ROA history
YEARROAYoY
-26.45 %-678.33%
4.57 %+2,320.98%
0.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc, identified by the ticker symbol ALPS and ISIN KYG0231P1081, is a corporate entity headquartered in Kuala Lumpur, Malaysia. The company officially entered the public markets through an initial public offering scheduled for October 31, 2025. While the specific sector and industry classifications are not explicitly defined in available records, the operational scope of the group is substantial and highly specialized, particularly through its subsidiary structure. Alps Group Inc serves as the parent company for Alps Life Sciences Inc., which operates as an integrated biotechnology platform. This subsidiary unifies research and development, medical services, and wellness solutions under a single ecosystem designed to enhance global healthcare outcomes. The firm has developed a diverse pipeline of initiatives spanning multiple advanced therapeutic areas. Key research focuses include MyImmune therapies utilizing natural killer cells, CAR-T cell technologies, and the development of COVID-19 mRNA vaccines. Additionally, the company is engaged in diabetes therapeutics and is advancing stem cell technologies, specifically induced pluripotent stem cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technologies. Beyond its biotechnological research, the company provides a range of aesthetic and general healthcare services. These offerings include both non-surgical and surgical aesthetic treatments, as well as broader cosmetic procedures and wellness services. To support its scientific endeavors, the company operates a molecular laboratory alongside a current Good Manufacturing Practice (cGMP) cell and gene therapy research and cultivation laboratory. This infrastructure enables the rigorous development and production of its advanced therapeutic candidates. The organization maintains a workforce of 89 employees, reflecting a focused operational model despite its broad scientific ambitions. The integration of high-level biotechnology research with direct-to-consumer aesthetic and wellness services creates a unique business model that bridges cutting-edge medical science with practical healthcare applications. The company's presence in Kuala Lumpur positions it within a growing Southeast Asian hub for medical innovation, leveraging local expertise to support its global healthcare mission. The upcoming IPO marks a significant milestone, potentially providing the capital necessary to expand its research pipeline and enhance its service offerings across its diverse operational domains. Alps Group is one of the most popular companies on Eulerpool.

ROA Details

Understanding Alps Group's Return on Assets (ROA)

Alps Group's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Alps Group's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Alps Group's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Alps Group’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Alps Group stock

Return on Assets (ROA) of Alps Group is -26.45 % in 2024.

Return on Assets (ROA) of Alps Group changed from 4.57 % to -26.45 %, representing a -678.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Alps Group since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Alps Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Alps Group

All Key Metrics — Alps Group